Extracorporeal photopheresis (ECP) may represent an alternative to immunosuppression, as a means of reducing rejection after thoracic organ transplantation. The mechanism by which ECP exerts its protective effects has, until now, remained elusive. We analyzed peripheral blood mononuclear cells of four children with chronic heart and lung transplant rejection, who received ECP in addition to conventional immunosuppressive treatment. The effects of ECP were evaluated at each cycle, comparing blood samples from the same patient collected before and after treatment. In vitro, peripheral blood mononuclear cells treated with ECP undergo apoptosis and are phagocytosed by immature dendritic cells, which, in turn, acquire a tolerogenic phenotype. The frequency of T cells, with a regulatory phenotype and strong suppressive activity, was significantly increased in the blood of ECP-treated patients. The immunomodulatory effects of ECP may be explained by its ability to increase the frequency of regulatory T cells with inhibitory action on transplant immune rejection.
xtracorporeal photopheresis (ECP) has been proposed as an alternative therapy for immune-mediated disease, including transplant rejection (1) . The treatment consists of exposing peripheral blood mononuclear cells (PBMC) to ultraviolet A (UVA) light, in the presence of 8-methoxypsoralen, a DNA-intercalating agent. The cells thus treated are reinjected into the same patient.
ECP was first used successfully for the treatment of cutaneous T-cell lymphoma (2) . In heart transplantation, ECP prevents chronic rejection (3, 4) , reduces acute rejection episodes (5) , and is associated with an increased number of apoptotic cells infiltrating the transplanted heart (4). In patients with graft-versus-host-disease, ECP reduces alloreactive T-cell responses (6, 7) ; a partial success has also been reported in type 1 diabetes (8) but ECP had no beneficial effect in multiple sclerosis (9) .
The mechanisms by which ECP exerts its protective effects are still poorly understood (1, 10) . It has been suggested that ECP-treated lymphocytes undergo apoptosis, but monocytes are more resistant (1, 3) . A modulation of dendritic cell (DC) subpopulations and a shift of cytokine profile from Th1 to Th2 have also been observed (7) .
A T-cell regulatory (Treg) population, actively involved in transplant tolerance, has been described (11, 13) . Treg cells are CD4 ϩ and constitutively express the IL-2 ␣ chain receptor (CD25 ϩ ) without activation markers (e.g. CD69, CD40L). Treg cells do not expand after T-cell receptor stimulation and express the cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) (11). The aim of our work was to study the effect of ECP on the immune system of heart-and lung-transplanted children.
Ten transplanted patients-five with heart and five with lung transplants-were enrolled in the study. Four patients-two with lung and two with heart transplants-were treated with ECP in addition to conventional immunosuppression. The remaining six patients received immunosuppressive therapy alone ( Table 1) .
The diagnosis of chronic rejection was based on the detection of coronary artery vasculopathy or bronchiolitis obliterans after heart or lung transplantation, respectively (14, 15) . Drug toxicity was the indication for the additional treatment with ECP. ECP was performed twice a week, 2 weeks per month, for a total of 6 months using the UVARR apparatus (Therakos, West Chester, PA). The protocol was approved by our institution's ethics committee and patients gave their informed consent. Five healthy individuals provided control PBMC. All four patients were analyzed for the first time when ECP treatment was already started (2-4 months from the start) and, since then, they were bled before and after each subsequent ECP cycle (at least three different time points).
To investigate the effects of ECP on PBMC, we compared the viability of leukocytes collected before and after ECP. We measured the frequency of apoptotic cells by annexin V binding in both ECP-treated and untreated cells, immediately and at 24 and 48 hours of culture. The results (Fig.  1A and B) showed that 60% of CD3 ϩ T cells and CD14 ϩ monocytes already underwent apoptosis after 48 hours in culture, only if they had been treated with ECP. Thus, the treatment basically consists of reinjecting cells that are on the verge of apoptosis. It was previously claimed that apoptosis induced by ECP preferentially targeted activated cells, but that monocytes were spared by the killing process and selectively survived (1, 3). Our data do not support this conclusion, because T, B, and NK cells and monocytes were equally susceptible to ECP-induced apoptosis in our study. In addition, activated cells were not detected in the blood of patients either before or after the ECP (data not shown).
Physiologically, apoptotic cells, resulting from the normal cellular turnover, are removed by DCs. We questioned whether DCs would also recognize and phagocytose ECPinduced apoptotic cells. Patients' PBMC, collected before or after ECP, were labeled with the cell-tracking reagent CMFDA and cultured together with unlabelled immature DCs. FACS analysis was performed after 24 hours. DCs could be distinguished from PBMC based on their larger size and different shape. CMFDA fluorescence was detected in the DC population incubated with ECP-treated PBMC, but not in the population cultured with ECPuntreated PBMC ( Fig. 2A) . This suggests that DCs had recognized and phagocytosed cells undergoing apoptosis after ECP.
In order to confirm this finding, we labeled patient's cells, collected either before or after ECP, with the vital DNA dye Hoechst 3342 and cultured them on a glass coverslip together with immature DCs. After 24 hours, ECP-treated PBMC had been phagocytosed and their Hoechst-stained nuclei could be visualized in the cytoplasm of DCs. No phagocytosis of untreated PBMC was observed (Fig. 2 B) .
Immature DCs become mature upon exposure to microbial products, whereas they acquire a tolerogenic phenotype in contact with apoptotic cells (13, 16, 17) . Mature DCs are characterized by the upregulation of major histocompatibility complex (MHC) class II (HLA DR), costimulatory molecules CD80, CD86, CD83, and secretion of TNF-␣. In contrast, tolerogenic DCs only upregulate MHC class II molecules (13, 16, 17) .
We compared the phenotype of immature DCs (Fig.  2C, thin line) to that of DCs induced to mature with LPS (Fig.  2C , thick line, right panels) or incubated with PBMC collected before (Fig. 2C, " pre," thick line, middle panel) and after ECP (Fig. 2C, "post," thick line, right panel) . We found that DCs cocultured with cells collected before ECP remained phenotypically immature, but DCs, which had phagocytosed ECPtreated PBMC, acquired a tolerogenic phenotype (13, 16) (Fig. 2C) .
It has been demonstrated that apoptotic cells in the blood collect in the spleen. Here, they are captured by resi- dent immature DCs (13, 16) , which in turn develop into tolerogenic DCs (13, 16) . It has also been shown that induction of tolerogenic DCs results in increased levels of circulated Treg cells (13, 16) . Similar mechanisms may be triggered by the intravenous injection of ECP-treated cells, which, as we have demonstrated, will die of apoptosis.
In the peripheral blood of ECP-treated patients, there was no major change in the frequency and activation status of T, B, and NK cells and monocytes (not shown).
In all four patients, the only significant change was an increased frequency of Treg cells (CD25 ϩ and CD69 Ϫ ), compared to healthy controls (14% vs. 7%. P Ͻ 0.05) (Fig. 3B) . In contrast, Treg cells were significantly diminished in transplanted children treated with conventional immunosuppressive therapy (4% vs. 7% healthy controls, P Ͻ 0,05; vs. 14% ECP-patients, P Ͻ 0.001) (Fig. 3A) . The increased frequency of Treg cells was a constant finding in all ECP-treated patients.
In order to prove that the population identified as Treg cells had a suppressive function, we compared the proliferation induced by CD3 and CD28 M-ab in either the total CD4 ϩ T cells or in CD4 ϩ T cells depleted of Treg. A 30 -60% increase of proliferation was observed by removing Treg cells (Fig. 3C) . These, upon T-cell receptor crosslinking, upregulated CTLA-4 surface expression (Fig. 3D) . Hence, CD4 ϩ
CD25
ϩ T cells of patients treated with ECP are functionally regulatory T cells.
Compared to conventional immunosuppressive drugs, the real advantage of ECP is that T-and B-cell responses to novel or recall antigens are conserved in ECP patients (18) . Thus ECP permits a balance between tolerance to the transplant and the physiological defense against invading pathogens. This balance is of vital importance for organ-transplanted patients not only because it is difficult to defeat infections in individuals who are immunosuppressed, but also because infections often trigger transplant rejection (15, 18) .
The idea that regulatory T cells could be the explana- tion for the immunomodulatory effects of ECP is not new (10), but has never been directly proven in organ-transplanted patients. On the other hand, the idea that tolerogenic DCs could be induced by ECP was not even contemplated. We indeed found that CD4 ϩ CD25 ϩ Treg cells, with immunosuppressive function, were significantly increased in the peripheral blood of ECP-treated patients. Most relevantly, we found that in two patients the levels of Treg cells were still higher than normal up to one year after the last ECP cycle and, only at that time, they started to decrease (data not shown). This finding illustrates the long-lasting effects of ECP, but also suggests that "recall" cycles may be necessary to maintain a constant frequency of Treg. In addition, as Treg cells were reduced in patients receiving conventional immunosuppressive therapy alone, an impairment of donor-specific transplant tolerance could be an important consequence of conventional immunosuppression.
During development, CD4 ϩ CD25 ϩ Treg cells originate in the thymus (16) . In the adult, an increased level of circulated Treg is induced by tolerogenic DCs (16, 17) . Our findings suggest that the generation of tolerogenic DCs and the induction of Treg cells explain the immunomodulatory effects of photopheresis. Recent evidence has indicated that the suppressive function of Treg cells is enhanced in vivo by Tr1 cells, another type of Treg with the ability to cause a systemic suppression mediated by IL-10 (12). We are currently exploring whether Tr1 cells may amplify the function of conventional Treg cells in organ-transplanted patients treated with ECP.
Our study was not designed to directly prove or disprove the clinical efficacy of ECP, but the treatment appeared to be beneficial (Table 1) . Clearly, the association between levels of Treg and an improved clinical outcome remains to be demonstrated in larger trials.
In summary, the elucidation of the immunological mechanisms trigged by ECP may represent the basis for optimizing current therapeutic protocols in the field of transplantation and for its introduction in the treatment of other immunological disorders. It remains to be seen whether the same immunological phenomena, identified after ECP in organ-transplanted patients, apply to the other conditions in which ECP is or has been used (e.g., cutaneous T-cell lymphoma, graft-versus-host disease, and autoimmune diseases). The unraveling of the basic mechanisms of ECP-
